Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H1 2018

  • ID: 4479904
  • Drug Pipelines
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bioprojet SCR
  • Griffin Discoveries BV
  • Johnson & Johnson
  • Novartis AG
  • Palau Pharma SA
  • Sensorion SA
  • MORE
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Histamine H4 Receptor - Pipeline Review, H1 2018'; Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies.

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - The histamine H4 receptor is a member of the G protein-coupled receptor super family.

H4 receptors modulate eosinophil migration and selective recruitment of mast cells leading to amplification of histamine-mediated immune responses and eventually to chronic inflammation. H4 receptor involvement in dendritic cell activation and T cell differentiation documents its immunomodulatory function.

The report 'Histamine H4 Receptor - Pipeline Review, H1 2018' outlays comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 7 and 1 respectively.

Report covers products from therapy areas Immunology, Ear Nose Throat Disorders, Ophthalmology, Respiratory and Dermatology which include indications Allergic Conjunctivitis, Plaque Psoriasis (Psoriasis Vulgaris), Acute Sensorineural Hearing Loss, Allergies, Asthma, Atopic Dermatitis, Cystic Fibrosis, Hearing Disorders, Idiopathic Pulmonary Fibrosis, Inflammation, Rheumatoid Arthritis, Rhino-Conjunctivitis, Vertigo, Vestibular Diseases and Vestibular Neuronitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bioprojet SCR
  • Griffin Discoveries BV
  • Johnson & Johnson
  • Novartis AG
  • Palau Pharma SA
  • Sensorion SA
  • MORE
Introduction

Report Coverage

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Overview

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development

Bioprojet SCR

Griffin Discoveries BV

Johnson & Johnson

Novartis AG

Palau Pharma SA

Sensorion SA

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles

azasetron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-7881A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-134 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-136 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-48 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-28610244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

toreforant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UR-63325 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZPL-389 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Products

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Product Development Milestones

Featured News & Press Releases

Feb 14, 2018 : Sensorion Presents New SENS-401 Data at ARO 2018 MidWinter Meeting

Jan 24, 2018 : Sensorion Announces Multiple Poster Presentations at the ARO 2018 MidWinter Meeting

Sep 12, 2017: Sensorion’s Oral Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent in Preclinical Study

Aug 22, 2017: Sensorion Announces FDA Orphan Drug Designation Granted to SENS-401 for Treatment of Cisplatin-Induced Ototoxicity in Pediatric Patients

Jun 08, 2017: Sensorion Takes a Key Step towards Phase 2 with SENS-401 Thanks to the Positive Results Obtained in the Phase 1 Clinical Trial

May 02, 2017: Sensorion Presents Preclinical Data for SENS-401 Demonstrating Protection against Cisplatin-Induced Hearing Loss in Animal Model

Mar 09, 2017: Sensorion Receives European Authorization to Initiate Phase II Clinical Trial of SENS - 111 to Treat Acute Vertigo

Feb 15, 2017: Sensorion Inner Ear Disease Product Candidates and Technology Subject of Multiple Presentations at ARO MidWinter Meeting 2

Feb 15, 2017: Sensorion Presents Poster on its Drug Candidate, SENS-401, at Association for Research in Otolaryngology Annual Meeting

Dec 14, 2016: Sensorion provides update on SENS-111 at ARO MidWinter Meeting 2

Dec 14, 2016: Sensorion provides update on SENS-401 at ARO MidWinter Meeting 2

Nov 24, 2016: Sensorion Receives Orphan Drug Designation in Europe for SENS-401 in Sudden Sensorineural Hearing Loss

Nov 17, 2016: Sensorion Presents New Preclinical Results with SENS-401 in Acute Sensorineural Hearing Loss at Neuroscience 2

Oct 17, 2016: Sensorion Obtains a Positive Opinion on Granting of Orphan Medicinal Product Designation for SENS-401 in Europe

Oct 06, 2016: Sensorion presented data from the caloric test with SENS - 111 at the EACPT conference

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Bioprojet SCR, H1 2018

Pipeline by Griffin Discoveries BV, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Palau Pharma SA, H1 2018

Pipeline by Sensorion SA, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bioprojet SCR
  • Griffin Discoveries BV
  • Johnson & Johnson
  • Novartis AG
  • Palau Pharma SA
  • Sensorion SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll